Eric Ingram and Sergio Gallucci of SCOUT are focused on creating data-driven solutions to space technology management to save companies billions and prevent space debris. Photos courtesy of SCOUT

A Virginia-based space company startup focusing on developing small and inexpensive satellites is making an out-of-this-world entrance in the Houston commercial innovation space.

SCOUT has been selected as part of the 2020 MassChallange's Texas in Houston cohort, a zero-equity startup accelerator, in the commercial space track and is planning a demonstration mission with the Johnson Space Center in 2021.

The startup, founded in 2019 by Eric Ingram and joined shortly after by Sergio Gallucci. Both have years of experience in innovative research and development, leading teams across academia, government, and industry. Their data will help manufacturers and operators extend satellite lifetimes, avoid failing satellites, reducing up to a billion dollars in losses.

"If we want further operate in space and grow our space presence overall," Eric Ingram, CEO-and-founder tells InnovationMap. "We need to have a safe environment to expand that presence so any time you have unchecked failures and space debris is a problem. We want to help take some of the riskiness out of space operations by providing data that doesn't already exist."

SCOUT provides a wide array of new products based on data to produce small and inexpensive satellites to perform in-space inspections of large and expensive satellites. Their data and spaceflight autonomy software helps spacecraft detect, identify, and refine models for observed objects to gather information and enable autonomous operations.

The space startup's observation and comprehension capabilities creates data products for customers, such as Spacecraft Sensor Suites and Satellite Inspections. The former is a sensor suite under current development to enable a new way to monitor satellites in space while the latter consists of their small satellites that can enable on-demand and on-site inspections for space assets.

This, according to Ingram, is changing the paradigm of operational risk in space.

"If we are able to better understand how these satellites age over time and diagnose problems before they become catastrophic failures," says Ingram "We can prevent space debris from even happening. The more safety and responsibility in space, the better it is for everyone to increase their technology and investment in what is a very rapidly growing industry."

Lost satellites tend to happen often, resulting in about $300 million lost in hardware and around $40 million annual revenue gone. Spacecrafts in outer space can be part of many unpredictable interactions that can be difficult to trace including solar activity, thermal, mechanical wear, and outgassing.

SCOUT will focus the rest of the year in growing their company, despite the setbacks caused by the coronavirus. Their priority is to meet their fundraising and technical milestones while engaging in strategic partnerships with satellite industry players.

"The space industry is growing and is becoming a more realistic and viable avenue for business growth and investment," says Ingram. "Houston is a diverse city with innovation at every front and the effort that NASA is going through to aid the commercial space industry, combined with the startup accelerators that there is a lot of adjacent opportunities and overlap in capabilities."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”